A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia.
Yunfei Chen, Yanmei Xu, Huiyuan Li...
https://pubmed.ncbi.nlm.nih.gov/38899695/Actively Recruiting
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2026-08-26
38
Participants Needed
1
Research Sites
4 weeks
Total Duration
Researchers are exploring a treatment approach for adults newly diagnosed with primary immune thrombocytopenia ITP, a condition characterized by a low platelet count. This prospective, single-arm, multicenter study will enroll 38 patients to evaluate the safety and effectiveness of combining standard-dose corticosteroids with thrombopoietin receptor agonists TPO-RA as initial therapy. The study also investigates a sequential multitarget combination strategy for patients who do not respond adequately to the initial treatment. During the core treatment phase lasting 12 weeks, patients will receive corticosteroids tapered off within 8 weeks alongside continuous TPO-RA therapy. For those with treatment failure after 2 weeks, the ongoing TPO-RA will be combined with either rituximab or an anti-CD38 monoclonal antibody as sequential combination therapy. Following this, during a 24-week follow-up and exploratory treatment phase, patients may receive switched TPO-RA combined with rituximab, anti-CD38 monoclonal antibody, or both, depending on prior treatments. The study concludes with a 4-week safety follow-up. Participants will undergo regular assessments of platelet counts, bleeding scores, and quality of life using questionnaires like the ITP-PAQ and SF-36. Researchers will monitor responses at multiple time points, including early response at 1 week and overall response at 12 weeks, with the primary outcome being the sustained response rate between weeks 13 and 36. Safety monitoring continues through the safety follow-up phase, with total participation spanning approximately 40 weeks.
CONDITIONS
Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia
X
Xiaofan Liu
R
Rongfeng Fu
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Institute of Hematology & Blood Diseases Hospital, China
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 weeks (Weeks 1-12)
Participants receive standard-dose corticosteroids combined with thrombopoietin receptor agonists for initial therapy. Corticosteroids are tapered off within 8 weeks, while TPO-RA treatment continues for 12 weeks. Patients with treatment failure after 2 weeks may receive additional drugs such as rituximab or an anti-CD38 antibody in combination with ongoing TPO-RA.
Duration - 24 weeks (Weeks 13-36)
Patients with treatment failure enter this phase lasting 24 weeks (Weeks 13-36). Those who did not receive combination therapy earlier will receive switched TPO-RA combined with rituximab or anti-CD38 antibody. Patients who received combination therapy earlier will receive switched TPO-RA combined with both rituximab and anti-CD38 antibody. TPO-RA treatment continues during this phase.
Duration - 4 weeks (Weeks 37-40)
Participants are monitored for safety and any adverse effects for 4 weeks after treatment completion (Weeks 37-40).
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Yunfei Chen, Yanmei Xu, Huiyuan Li...
https://pubmed.ncbi.nlm.nih.gov/38899695/Francesco Rodeghiero, Roberto Stasi, Terry Gernsheimer...
https://pubmed.ncbi.nlm.nih.gov/19005182/Sif Gudbrandsdottir, Henrik Sverre Birgens, Henrik Frederiksen...
https://pubmed.ncbi.nlm.nih.gov/23293082/Cindy Neunert, Deirdra R Terrell, Donald M Arnold...
https://pubmed.ncbi.nlm.nih.gov/31794604/Drew Provan, Donald M Arnold, James B Bussel...
https://pubmed.ncbi.nlm.nih.gov/31770441/Institute of Hematology & Blood Diseases Hospital, China
Lead Sponsor